Jul 1 |
Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)
|
Jun 5 |
Ventyx reports preclinical results for anti-obesity drug VTX3232
|
Jun 5 |
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
|
May 16 |
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
|
May 16 |
Ventyx Biosciences gets new operations chief
|
May 16 |
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
|
May 13 |
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
|
May 11 |
Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript
|
May 9 |
Ventyx Biosciences GAAP EPS of -$0.62 beats by $0.05
|
May 9 |
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
|